Team | CBD Global, LLC

CBD Global Product Catalog

Sales Associate Position

powered by Typeform

US Department of Health and Human Services (HHS) - Patent US6630507B1

"Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidiol, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH3, and COCH3."

Read Entire Patent 507

Leave A Review For CBD Global

Leave A Review

Customer Reviews

A truly reliable company in the cannabis space!

May 24, 2020

These guys go above and beyond from their products and formulations to their customer support, standardization practices, and documentation. They’ve been a key partner in helping us with our online CBD e-commerce store providing us with all necessary documents when needed, high-quality branded products, and team support. I highly recommend working with CBD Global!!

Dustin ~ ReleafCBD.com

Oncology Formula

January 8, 2022

I ordered a 120 ml bottle of your oncology/immunity terpenes in April of this year. I had been diagnosed with Lymphoma which was progressing to Leukemia, most likely from exposure to Agent Orange when I was serving in Vietnam with the Australian forces.

My white cell count has been rising steadily for three years, and I had my regular blood test after I had been using your product for about 6 months.

The cancer specialist stated that my white cell count had plateaued and even started to decline. This is unusual with Leukemia and I told him the only change I made was using your oil. He did not say much about it except to keep using it if I thought it was helping, which I obviously believed it was. I have gone immediately from 6 monthly checks to yearly checks and he seemed to think that it was unlikely to require anything more than that.

Further to that my niece had been diagnosed with breast cancer, had chemo and surgery to remove the lumps. After about a year they started to re-appear, so I made her up some oil and sent it to her. After using it for three months she went in for her check up and the new tumors had pretty much shrunk to nothing and they could find no problems with her blood tests. She also told her specialist that the only change she had made was using your oil and he pretty much said the same thing as my cancer guy.

In a nutshell, thank you very much from myself and my niece. I believe your product has made the difference.

John Dunne

See All Reviews

EDITING TECHNIQUES USED

Genome sequencing of specific cannabis strains

Genome sequencing of specific cannabinoids (THC-A Synthase)

Chemical Mutanagenesis

Gene Gun Editing

Agrobacterium Mediated Transformation

Hemoscreen™ Summary

(Cannabinoid Blood Tests)

This convenient and portable blood test kit is designed for clinical environments and for use by healthcare practitioners assisting and monitoring patient volunteers. Hemoscreen™ measures bioavailable absorption rates of medications and their associated blood concentration levels over time. These absorption rates change based on the delivery method of each unique product.

The first correlation of data associates a product to its measured max absorption. The second data set completes the bell curve showing the longevity and half-life of cannabinoids within the blood. The combined data is used to establish the most reasonably accurate dosage and regimen plans for patients that the cannabis industry has seen to date.

Hemoscreen™ is providing valuable information to further improve the ongoing development of efficacious cannabinoid medications.

Prague Facility

Extraction Science

Our exclusive European partnership provides direct access to:

A Schedule 1 Controlled Substance Licensed facility.

A sister Pharmaceutical research company for conducting clinical trials on cannabinoids and medical devices.

Standardized production of new Minor-Cannabinoid Predominant (MCP) oils and isolates (CBG, CBC, CBN, CBDV).

Synthetic CBD, CBC, and semi-synthetic CBN for research APIs.

An entire department of cannabis chemists focused on cutting edge research and innovation.

Close relationships with state authorities and regulators.

TrueNano™ Backscatter Sample Test Results

True Nano Water BackScatter Test 1 CBD Global

True Nano Water BackScatter Test 2 CBD Global

Research & Development

Education
Academic Collaboration
Genetic Species Development
Cell Culturing
Tissue Propagation
Clinical Studies & Patient Monitoring
Data Collection & Evaluation For Future R&D

Product Formulation

Research Data Analysis to Product Concept
Formulation & Production
Transparency Batch Tracking
In House Design & Development
In House Marketing & PR
Sales & Distribution (Wholesale & Retail)

Radioligand Binding Summary

(CB1/CB2 receptor binding affinity of cannabinoids)

The binding affinity of cannabinoids to their respective cell surface receptors (CB1/CB2) is being measured by using existing techniques of binding ligand molecules to cannabinoids and following them to specific, targeted sites. Successful binding is determined electrochemically or through fluorescence detection method. This form of analytic test identifies the presence of target molecules in a sample known to bind to receptors of interest.

This procedure is being utilized to identify any potential changes in binding affinity that may be caused by the differences between a patient receiving natural phytocannabinoids vs. derivative salts, isomers or synthesized versions. Additionally, changes in cellular metabolism may be seen between species of cannabis and their associated full plant spectrums.

Ultimately, this allows for the most accurate means of mapping specific forms of disease to patient demographics and the treatment values of different cannabis plant species. Physicians and health care practitioners can be better equipped to align and recommend the appropriate cannabis phenotype profiles for specific medicines needed by each unique patient.

Analytics & Testing

Pre/Post Harvest Potency Testing
Oils & Isolates Full Panel Testing (Potency, Solvents, Pesticides, Microbials, Metals)
Water Soluble Powders & Liquids Potency Testing
Finished Consumer Goods Potency Testing
Nano Particle Size Testing
Terpene Testing
2-AG/Anandamide, CBD/THC Metabolite Blood Analysis
Radioligand Binding Assays

Cultivation & Extraction

Controlled Breeding
Precision Cultivation
Harvesting/Storage
Extraction & Post Processing
Refinement/Distillation/Dewaxing/Isolation
Chain-of-Custody

Cultivated Seed Lot

Material Harvest Sheet

Safety Data Sheet

Seed Purchase Specs

Certificate Of Analysis

Certificate of Origin

REFINED CBG SAMPLE COA

Oils & Isolates

Next Gen Formats

Terpenes

Brands

Services

Nobody Can Do Big Things On Their Own

Finding good people and forging great teams takes time

CBD Global is blessed to have such a strong group of talented individuals who are dedicated to each other on a singular mission with a shared belief:

US Management Team

Scott Holden

Dustin Lato

Taj Ray

Hunter Harrison

Jared Clark MBA, J.D., PMP

Jennifer Ellis, MBA

Jennifer Phillips, CPA, MST

Timothy Fry

EU Management Team

Jan Storch, Ph.D.

Miroslav Richter

Jan Sykora, Ph.D

Medical & Academic Advisors

Robert Sievers, Ph.D

Randall Shearer, Ph.D

Ling Yuan, Ph.D

Mike Limberg, MD

Information

Support

Connect